Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
Grant support
R01 AG054025
NIA NIH HHS - United States
R01 NS094557
NINDS NIH HHS - United States
PubMed
28453485
DOI
10.3233/jad-170048
PII: JAD170048
Knihovny.cz E-resources
- Keywords
- Alzheimer’s disease, oligomers, serum, tau protein,
- MeSH
- Alzheimer Disease blood cerebrospinal fluid complications MeSH
- Amyloid beta-Peptides blood cerebrospinal fluid MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Cognitive Dysfunction blood etiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Peptide Fragments blood MeSH
- tau Proteins blood cerebrospinal fluid chemistry MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Aging blood MeSH
- Mental Status Schedule MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
- Names of Substances
- Amyloid beta-Peptides MeSH
- Peptide Fragments MeSH
- tau Proteins MeSH
Although tau protein was long regarded as an intracellular protein with several functions inside the cell, new evidence has shown tau secretion into the extracellular space. The active secretion of tau could be a physiological response of neurons to increased intracellular amounts of tau during the progression of tau pathology. We looked for potential differences in the serum levels of toxic tau oligomers in regards to cognitive impairment of subjects. We detected tau oligomers in the serum of Alzheimer's disease (AD) patients, but they were also present to some extent in the serum of healthy older subjects where the levels positively correlated with aging (Spearman r = 0.26, p = 0.016). On the contrary, we found lower levels of tau oligomers in the serum of mild cognitive impairment (MCI) (p = 0.033) and MCI-AD (p = 0.006) patients. These results could suggest that clearance of extracellular tau proteins takes place, in part, in the periphery. In the case of MCI patients, the lower levels of tau oligomers could be the result of impaired clearance of tau protein from interstitium to blood and consequent accumulation of tau aggregates in the brain.
3rd Faculty of Medicine Charles University Prague Czech Republic
Mitchell Center for Neurodegenerative Diseases University of Texas Medical Branch Galveston TX USA
References provided by Crossref.org